Sign inJoin waitlistJoin the waitlist

Ethel Weld

Associate Professor of Medicine · Johns Hopkins University School of Medicine

Credentials: · · · · ·

History

Johns Hopkins University School of Medicine
Present

Infectious Disease
Johns Hopkins University School of Medicine
2007–2009
Internal Medicine
2006–2009
University of Chicago Division of the Biological Sciences, The Pritzker School of Medicine
2002–2006

Research

Interest of Youth Living With HIV in Long-Acting Antiretrovirals
Journal of acquired immune deficiency syndromes · 2019 · First of 10 authors · 68 citations
Ethical issues in therapeutic use and research in pregnant and breastfeeding women
Review · British Journal of Clinical Pharmacology · 2022 · First of 3 authors · 50 citations
Long-acting implants to treat and prevent HIV infection
Current Opinion in HIV and AIDS · 2020 · First of 2 authors · 47 citations

CH
Craig Hendrix
13 papers
Allison Agwu
4 papers
CF
Charles Flexner
4 papers
Kelly Dooley
4 papers
Susan Swindells
4 papers
Anthony Garcia-Prats
3 papers
Eileen Scully
2 papers
ES
Eugenie Shieh
2 papers · 1 as a fellow
HS
Hans Spiegel
2 papers
HH
Hiwot Hiruy
2 papers
IM
Ian Mcgowan
2 papers
Joel Blankson
2 papers

Grants

Optimizing the Use of Long-Acting Antiretrovirals for Youth Living withHIV
National Institute of Allergy and Infectious Diseases · K23
Contact PI · $702K · Johns Hopkins University
2021–2026

Clinical trials

Dolutegravir/Lamivudine Dual Therapy for ART-naïve People With HIV and TB Receiving Rifampin-based TB Treatment
Principal investigator · Recruiting · Phase 3
Johns Hopkins University
2025–2029
Optimization of a Tenofovir Enema for HIV Prevention
Principal investigator · Completed · Phase 1
Johns Hopkins University
2016–2019
Study of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children With Rifampicin-Resistant Tuberculosis
Study chair · Completed · Phase 1
National Institute of Allergy and Infectious Diseases (NIAID)
2023–2026
Evaluating the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination With Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in Children With MDR-TB With and Without HIV
Study chair · Completed · Phase 1, Phase 2
National Institute of Allergy and Infectious Diseases (NIAID)
2019–2025